Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567445 | 0.91 | TNKS2 (0.41) | RARGRXRAPPARGALDH1A1TNKS2 | |
| SCHEMBL6567275 | 0.87 | TNKS2 (0.33) | NR3C1NR3C2TNKS2 | |
| SCHEMBL6567472 | 0.86 | DHFR (0.38) | RARGRXRAPPARGALDH1A1TNKS2 | |
| SCHEMBL6567280 | 0.86 | DHFR (0.37) | ALDH1A1NR3C1NR3C2TNKS2HTR2A | |
| SCHEMBL6567276 | 0.85 | PTGS2 (0.38) | — | |
| SCHEMBL6565760 | 0.84 | MAPT (0.36) | RARGRXRAPPARGCYP4F2CYP4A11 | |
| SCHEMBL7792867 | 0.83 | FFAR4 (0.41) | RARGRXRAPPARGALDH1A1KMT2A | |
| SCHEMBL7940316 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP4F2CYP4A11KMT2A | |
| SCHEMBL4166761 | 0.80 | ALDH1A1 (0.42) | ALDH1A1NR3C1NR3C2TNKS2CYP4F2 | |
| SCHEMBL3814419 | 0.80 | ESR1 (0.39) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1484334-A2 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040225145-A1 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-11 | — | — | US | disclosed |
| EP-0823435-B1 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL CO (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6242514-B1 | CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-5914361-A | IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-06-22 | — | — | US | disclosed |
| US-5889095-A | OXYGEN AND HEAT RESISTANCE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0823435-A2 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225145-A1 | Process for producing phosphite | PHOSPHO1, PLCG1, PLCG2 | RARG 3143/4885RXRA 3059/4885PPARG 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.